SCHEMBL4987351

SCHEMBL4987351

O=C(O)c1ccc(-c2ccccc2Cl)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
NPSR1 Q6W5P4 1/20 1.00
RAB9A P51151 2/20 0.68
MAPT P10636 2/20 0.68
LMNA P02545 1/20 0.68
MAPK1 P28482 1/20 0.68
CASP3 P42574 1/20 0.68
RECQL P46063 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
SENP7 Q9BQF6 1/20 0.68
ERCC5 P28715 1/20 0.66
FEN1 P39748 1/20 0.66
SLC9A1 P19634 1/20 0.63
NPC1 O15118 1/20 0.61
HPGD P15428 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HSD17B10 Q99714 1/20 0.61
TDP1 Q9NUW8 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352723 1.00 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL14825074 0.86 ALDH1A1 (0.76) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL28269605 0.86 ALDH1A1 (0.75) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL4036255 0.84 ALDH1A1 (0.73) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL4942886 0.81 ALDH1A1 (0.69) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL11634779 0.81 ERCC5 (0.68) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL10028045 0.80 RAB9A (0.69) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL21067946 0.80 RAB9A (0.69) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL11085446 0.80 MEN1 (0.67) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL12670456 0.79 ALDH1A1 (0.68) ALDH1A1MEN1KMT2ANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052365-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2006-03-09 US claimed
JP-2006505526-A 2006-02-16 JP claimed
EP-1539178-A2 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2005-06-15 EP claimed
WO-2004017911-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-04 WO claimed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
CN-116535371-A Guanidine-containing phenyl furan carboxamide compound and application thereof 华南农业大学 2023-08-04 CN disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 US disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
CN-110294749-B (S) -1, 3-thiazole phenyl furan thiocarbamate compound and preparation method and application thereof 华南农业大学 2022-01-25 CN disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
CN-110183428-B Furan thiocarbamate compound containing 1,2,3, 4-tetrazole and preparation method and application thereof 华南农业大学 2021-08-03 CN disclosed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 US disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 EP disclosed
US-7939554-B2 Of Src homology protein tyrosine phosphatase 1; phenyl isothiazolones or a benzo-1,4-quinone; antineoplastic agents; immunostimulants inducing a cytokine response; side effect reduction THE CLEVELAND CLINIC FOUNDATION (US) 2011-05-10 US disclosed
WO-2010065881-A2 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT ZAFGEN CORPORATION (US) 2010-06-10 WO disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed
US-20080103160-A1 Protein phosphatase inhibitors THE CLEVELAND CLINIC FOUNDATION 2008-05-01 US disclosed
US-20060052365-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2006-03-09 US disclosed
EP-1539178-A2 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2005-06-15 EP disclosed
WO-2004017911-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052365-A1 Protease inhibitors CTSS, CTSE, CMA1 ALDH1A1 1528/4885MEN1 3726/4885KMT2A 3606/4885
US-20080103160-A1 Protein phosphatase inhibitors PPM1A, DUSP15, PPM1B ALDH1A1 1282/4885MEN1 3553/4885KMT2A 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.